ClinicalTrials.gg
RecruitingNCT05956912Updated Jul 24, 2023

Implementing Group Metacognitive Therapy in Cardiac Rehabilitation Services (PATHWAY-Beacons)

An observational study in Anxiety, Depression and Cardiac Rehabilitation, sponsored by University of Manchester. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-07-24.

Primary conditionDepressionRegistry: Anxiety DisordersReclassifiedWhy we changed it
Registry
Anxiety Disorders — the first condition term the registry derived for this study.
ClinicalTrials.gg
Depression
Why
  1. The registry often attaches Anxiety Disorders to studies about something else, and this study's title and listed conditions do not name it.
  2. The study's listed conditions name Depression.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by University of Manchester · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2023, 3 years 2 months ago, but the record still lists the study as recruiting.
  • Started Sep 2022; still recruiting 4 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
100
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Depression by University of Manchester — 3 open to participants now, 3 under way, none of them phase 3. Depression · University of Manchester.

Started
2022
with 1 other
Observational
4 of 13
2 open now
Registered
12th of 13
by date

Among the 13 studies in Depression by University of Manchester, this one is one of 2 that started in 2022, is one of 4 observational ones, and was the 12th registered.

Depression

8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.

Browse Depression studies →

Open to participants now

3 of the 13 studies in Depression by University of Manchester are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Depression by University of Manchester, or all of them as a file.
02

Study summary

Background: Cardiac rehabilitation (CR) services aim to improve heart disease patients' health and quality of life and reduce the risk of further cardiac events. Depression and anxiety are common among CR patients, and current psychological treatments for cardiac patients have minor effects. However, the NIHR-funded PATHWAY trial found that group Metacognitive Therapy (MCT) was associated with improvements in anxiety and depression when added to CR and was more effective than usual CR alone. Group MCT was also associated with preventing anxiety and depression. The next steps will establish beacon sites for delivering MCT and pilot-test additions to the national audit of cardiac rehabilitation (NACR) data capture mechanism to include an MCT data field. Such steps will support a quantitative and qualitative evaluation of implementation.

Methods: The investigators aim to address questions concerning the quality of patient data recorded, level of adoption at sites, the characteristics of patients attending MCT, the impact of adding MCT to CR on mental health outcomes, and patient, healthcare staff and commissioner views of barriers/enablers to implementation. The investigators will deliver training in group MCT to CR staff from CR services across England. The investigators will conduct semi-structured qualitative interviews with CR staff trained in group MCT to assess views on the training programme, including successes and barriers to implementation of training and delivery. The investigators will interview 8-10 CR stakeholders to identify any barriers to implementation and how these might be resolved.

Discussion: The study will support development of an NHS roll-out strategy and systematic data collection that can be used to evaluate wide-scale implementation. The study can benefit service users by improving patients' mental health outcomes and CR practitioners' clinical skills. Results will be disseminated via peer-reviewed journals, national and international conferences and service user/voluntary sector organisations and networks.

03

Conditions studied

  • Anxiety
  • Depression
  • Cardiac Rehabilitation

Browse trials for

04

In context

Depression Reclassified

8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.

This study's planned enrollment of 100 is below the median of 175 across 1,261 observational studies indexed under Depression.

Browse Depression studies →

Lead sponsor

University of Manchester is the lead sponsor of 201 studies on the registry; 44 are open to participants now.

Compared within Depression, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Anxiety Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Cardiac rehabilitation staff trained in delivering Group-MCT, wider cardiac rehabilitation staff and managers, and healthcare professionals from local clinical commissioning groups.

All CR patients attending cardiac rehabilitation.

Eligibility criteria

Qualitative Inclusion Criteria:

All CR staff must meet the following inclusion criteria to be eligible:

  1. Be a healthcare professional working with cardiac rehabilitation services being trained to deliver group-MCT
  2. Be a healthcare professional working with cardiac rehabilitation or be a professional working at the commissioner level
  3. Minimum of 18 years old
  4. Competent level of English Language skills (able to read, understand and complete interviews in English).

Exclusion Criteria:

  1. Below 18 years of age
  2. Not a healthcare professional or professional working at the commissioner level
  3. Does not have a competent level of English language skills

Audit inclusion criteria:

All patients attending CR who meet the NICE recommendations for acute coronary syndrome (NG185) and heart failure (NG106) will be offered group MCT as part of routine CR.

06

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
100 participants (estimated)
Target follow-up
6 Months
Patient registry
Yes
07

What researchers measure

Primary outcomes

  1. Adoption of group MCT

    Successful adoption of group MCT at each site is set a-priori. A traffic-light criteria will be used to determine successful adoption. 1. Green - achieved all of the following: a) Delivered two 6-session group MCT courses (b) at least three patients per group, and (c) a combined total of at least 60% attending four or more sessions. 2. Amber - achieved one of the three criteria given above. 3. Red - achieved none of the criteria. A Green rating indicates that a site has fully met the criteria for successful adoption. Red indicates a failure to meet the requirements. Amber is partial adoption, where amendments to procedures and protocols might lead to successful adoption. At Amber sites, specific qualitative work will be undertaken to understand the reasons for not meeting criteria more fully and to help develop strategies to ameliorate this. An overall assessment will be made considering the traffic-light ratings of all six beacon sites.

    Time frame: Within the 6 months that MCT is being delivered in CR services

Secondary outcomes

  1. Dartmouth Coop

    The COOP will be captured through the National Audit for Cardiac Rehabilitation. It is a self-report measure designed to evaluate the functional abilities of medical patients. It consists of nine items covering various areas such as physical function, daily activities, pain, social activities, social support, emotions, overall health, changes in health, and quality of life. Each chart includes text and illustrations to assist the user in responding. The responses are graded on an ordinal scale of 1 to 5, with one being the best score.

    Time frame: Initial Cardiac Rehabilitation Assessment (Baseline) & Within 6 months of attending cardiac rehabilitation (Discharge)

  2. Semi-structured interviews will explore the views and opinions of group-MCT in CR (CR staff trained in group-MCT)

    To understand what CR staff views of training in group MCT are with a view to understanding enablers and barriers. To understand the consequences, both expected and unexpected, of implementing group-MCT, for example on existing CR services, staffing needs, administration and resource requirements.

    Time frame: 1 month prior to training in MCT

  3. Semi-structured interviews will explore the views and opinions of group-MCT in CR (CR staff trained in group-MCT)

    To understand what CR staff views of training in group MCT are with a view to understanding enablers and barriers. To understand the consequences, both expected and unexpected, of implementing group-MCT, for example on existing CR services, staffing needs, administration and resource requirements.

    Time frame: Within 1 month of delivering the pilot group of MCT

  4. Semi-structured interviews will explore the views and opinions of group-MCT in CR (CR staff trained in group-MCT)

    To understand what CR staff views of training in group MCT are with a view to understanding enablers and barriers. To understand the consequences, both expected and unexpected, of implementing group-MCT, for example on existing CR services, staffing needs, administration and resource requirements.

    Time frame: Upon completion of delivering group-MCT, approximately 5 months after starting the delivery of MCT in CR

  5. Semi-structured interviews will explore the views and opinions of group-MCT in CR (CCG and other management stakeholders)

    To understand the acceptability and feasibility of roll-out at commissioner level and what the enablers or barriers are. To understand the consequences, both expected and unexpected, of implementing group-MCT, for example on existing CR services, staffing needs, administration and resource requirements.

    Time frame: Through implementation of MCT in CR services, approximately 7 months.

  6. Hospital Anxiety and Depression Scale (HADS)

    The HADS will be captured through the National Audit for Cardiac Rehabilitation. It is a 14-item self-report questionnaire that measures symptoms of anxiety (7 items) and depression (7 items). Items are rated using a 4-point (0-3) scale, with higher scores indicating elevated distress. Scores for each subscale range from 0 to 21 and can be categorised as normal (0-7), mild (8-10), moderate (11-14), or severe (15-21).

    Time frame: Initial Cardiac Rehabilitation Assessment (Baseline) & Within 6 months of attending cardiac rehabilitation (Discharge)

08

Study locations

1 of 1 sites recruiting
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2022 (actual). Primary completion is estimated for Aug 2023, 11 months after the start.

Of 463 non-industry observational studies under Depression, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 63. This study's planned 11 months is below that.

Counting every sponsor, half of 496 studies reached it within 32 months; a quarter within 13 and three quarters within 61.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2023
First posted
Jul 24, 2023
StartActual
Sep 6, 2022
Primary completionEst.
Aug 31, 2023
CompletionEst.
Aug 31, 2023
Last update
Jul 24, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05956912
Collaborators
Greater Manchester Mental Health NHS Foundation Trust, University of York, National Institute for Health Research, United Kingdom
Responsible party
Adrian Wells (Professor of Clinical and Experimental Psychopathology, University of Manchester) — Principal investigator
First posted
Jul 24, 2023
Start date
Sep 6, 2022
Primary completion
Aug 31, 2023 (estimated)
Completion
Aug 31, 2023 (estimated)
Last update
Jul 24, 2023

Study contacts

Adrian Wells, PhD
Contact
adrian.wells@manchester.ac.uk
01612765399
Lora Capobianco, PhD
Contact
lora.capobianco@gmmh.nhs.uk
01610046664
Adrian Wells, PhD
principal investigator · University of Manchester

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion